Journal article
Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena
Abstract
BACKGROUND: In clinical trials, the two anti-interleukin (IL)-5 monoclonal antibodies (mAbs: mepolizumab and reslizumab) approved to treat severe eosinophilic asthma reduce exacerbations by ∼50-60%.
OBJECTIVE: To observe response to anti-IL-5 mAbs in a real-life clinical setting, and to evaluate predictors of suboptimal response.
Authors
Mukherjee M; Forero DF; Tran S; Boulay M-E; Bertrand M; Bhalla A; Cherukat J; Al-Hayyan H; Ayoub A; Revill SD
Journal
European Respiratory Journal, Vol. 56, No. 4,
Publisher
European Respiratory Society (ERS)
Publication Date
10 2020
DOI
10.1183/13993003.00117-2020
ISSN
0903-1936